Education
About Us
Working with TipRanks
Follow Us
PROCEPT BioRobotics (PRCT)
NASDAQ:PRCT
PRCT Stock Chart & Stats
$30.38
-$0.85(-0.97%)
At close: 4:00 PM EST
$30.38
-$0.85(-0.97%)
Day’s Range― - ―
52-Week Range$27.80 - $79.26
Previous CloseN/A
Volume113.34K
Average Volume (3M)1.18M
Market Cap
$1.70B
Enterprise Value$1.77B
Total Cash (Recent Filing)$294.28M
Total Debt (Recent Filing)$78.93M
Price to Earnings (P/E)―
Beta0.99
Next Earnings
Mar 03, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding55,878,590
10 Day Avg. Volume981,643
30 Day Avg. Volume1,182,348
Financial Highlights & Ratios
PEG Ratio2.10
Price to Book (P/B)10.43
Price to Sales (P/S)18.70
P/FCF Ratio-40.50
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue5.91
Enterprise Value/Gross Profit9.16
Enterprise Value/Ebitda-23.71
Forecast
1Y Price Target
$49.86Price Target Upside64.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.14
Revenue Forecast (FY)$422.08M
Bulls Say, Bears Say
Bulls Say
Installed-base Utilization InitiativesAnalyst highlights targeted initiatives to increase utilization of the existing installed base, which could lift procedure volumes and recurring revenue as commercial onboarding improves.
Leadership And Commercial StrategyAnalyst notes that new CEO Larry Wood's emphasis on improved commercial onboarding and execution may accelerate adoption and strengthen long‑term revenue dynamics.
Path To ProfitabilityAnalyst points to an achievable path to adjusted EBITDA and free cash flow breakeven by 2027, supported by mix-driven margin expansion and operational efficiencies.
Bears Say
Decelerating Operational MetricsAnalyst highlights slowing system representative productivity and moderating utilization growth, which could constrain upside to procedural volumes and installed‑base momentum.
Inventory And Field DestockingAnalyst warns that inventory destocking in the field could pressure sales visibility and amplify concerns about stocking rates and days inventory outstanding.
Salesforce Disruption And Longer Sales CyclesAnalyst cautions that salesforce changes and longer sales cycles for HYDROS may delay system placements and weigh on near‑term revenue.
PROCEPT BioRobotics News
PRCT FAQ
What was PROCEPT BioRobotics’s price range in the past 12 months?
PROCEPT BioRobotics lowest stock price was $27.80 and its highest was $79.26 in the past 12 months.
What is PROCEPT BioRobotics’s market cap?
PROCEPT BioRobotics’s market cap is $1.70B.
When is PROCEPT BioRobotics’s upcoming earnings report date?
PROCEPT BioRobotics’s upcoming earnings report date is Mar 03, 2026 which is in 44 days.
How were PROCEPT BioRobotics’s earnings last quarter?
PROCEPT BioRobotics released its earnings results on Nov 04, 2025. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.412 by $0.032.
Is PROCEPT BioRobotics overvalued?
According to Wall Street analysts PROCEPT BioRobotics’s price is currently Undervalued.
Does PROCEPT BioRobotics pay dividends?
PROCEPT BioRobotics does not currently pay dividends.
What is PROCEPT BioRobotics’s EPS estimate?
PROCEPT BioRobotics’s EPS estimate is -0.32.
How many shares outstanding does PROCEPT BioRobotics have?
PROCEPT BioRobotics has 55,878,590 shares outstanding.
What happened to PROCEPT BioRobotics’s price movement after its last earnings report?
PROCEPT BioRobotics reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.412. Following the earnings report the stock price went down -9.737%.
Which hedge fund is a major shareholder of PROCEPT BioRobotics?
Currently, no hedge funds are holding shares in PRCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PROCEPT BioRobotics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.86 (64.12% Upside)
$49.86 (64.12% Upside)
Blogger Sentiment
Bullish
PRCT Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 7.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.05%
12-Months-Change
Fundamentals
Return on Equity
-27.22%
Trailing 12-Months
Asset Growth
36.72%
Trailing 12-Months
Company Description
PROCEPT BioRobotics
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
PRCT Company Deck
PRCT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects strong revenue growth and significant increases in both U.S. and international sales, alongside positive gross margin expansion. However, persistent net losses, challenges in utilization growth, and anticipated procedural headwinds present concerns. The company remains optimistic about its strategic initiatives and long-term growth potential.View all PRCT earnings summariesPRCT Stock 12 Month Forecast
Average Price Target
$49.86
▲(64.12% Upside)
Technical Analysis
Alphatec Holdings
―
Artivion
―
LivaNova
―
Inspire Medical Systems
―
SS Innovations International
―
Ownership Overview
3.04% Insiders
37.54% Mutual Funds
0.10% Other Institutional Investors
43.83% Public Companies and Individual Investors